Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 2 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Entera Bio Ltd | ENTX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.01 | 06:00:01 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.01 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 1 | 2 | - | 0.52 - 3.35 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 06:24:26 | 2 | US$ 2.01 | USD |
Entera Bio Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 71.32M | 35.48M | - | 49k | -8.89M | -0.25 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Entera Bio News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ENTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.05 | 2.2575 | 1.91 | 2.04 | 178,704 | -0.04 | -1.95% |
| 1 Month | 1.90 | 3.35 | 1.65 | 2.37 | 420,198 | 0.11 | 5.79% |
| 3 Months | 0.75 | 3.35 | 0.6801 | 1.97 | 252,777 | 1.26 | 168.00% |
| 6 Months | 0.6551 | 3.35 | 0.52 | 1.67 | 157,514 | 1.35 | 206.82% |
| 1 Year | 0.69 | 3.35 | 0.52 | 1.50 | 96,153 | 1.32 | 191.30% |
| 3 Years | 3.35 | 8.68 | 0.4722 | 5.02 | 372,616 | -1.34 | -40.00% |
| 5 Years | 4.2612 | 10.16 | 0.4722 | 4.81 | 812,446 | -2.25 | -52.83% |
Entera Bio Description
| Entera Bio Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The company's product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The company recently completed the phase 2 study for EB613. The company also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. |
